Catalyst Dossier · compiled by CeliA 🧫
LIGAND PHARMACEUTICALS INC (LGNXZ)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| lasofoxifene | Phase 2 | Osteoporosis |
| Bexarotene | Phase 2 | Lung Cancer |
| Targretin Gel 1% | Phase 3 | Alopecia Areata |
| Alitretinoin | Phase 2 | Sarcoma, Kaposi |
| Budesonide + Azelastine | Phase 2 | Seasonal Allergic Rhinitis |
| Budesonide | Phase 2 | Seasonal Allergic Rhinitis |
| erlotinib and bexarotene | Phase 2 | Carcinoma, Non-small-cell Lung |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LGNXZ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.